In June the US Supreme Court held in Association for Molecular Pathology, et al. v. Myriad Genetics, Inc., that isolated segments of naturally occurring DNA are not eligible for patent. Although human intervention is required to isolate naturally occurring DNA, that DNA segment is still naturally occurring and therefore ineligible for protection under US patent law. Synthetic DNA was held to be patentable.